We searched PubMed with the term “endometrial cancer” in combination with the terms “epidemiology”, “pathology”, “pathogenesis”, “risk factors”, “prevention”, “diagnosis”, “staging”, “prognostic factors”, “tamoxifen”, “surgery”, “radiotherapy”, “hormonotherapy”, and “chemotherapy”. We mainly included results from randomised trials undertaken by large groups such as the Gynaecological Oncology Group and the European Organisation for Research and Treatment of Cancer. We also refer to
SeminarEndometrial cancer
Section snippets
Pathology
Pathological examination is the cornerstone of diagnosis of endometrial cancer (figure 1). About 80% of all endometrial carcinomas are of the endometrioid type (figure 2); this term refers to endometrial-type glands of varying differentiation easily recognisable on microscopy.10 Several subtypes or variants of endometrioid carcinoma have been described, such as secretory carcinoma and villoglandular carcinoma (panel 1). The former resembles a secretory endometrium, because glycogen vacuoles are
Pathogenesis
The endometrium undergoes structural modification and changes in specialised cells in response to fluctuations of oestrogen and progesterone during the menstrual cycle. Long-lasting unopposed oestrogen exposure leads to endometrial hyperplasia, which increases the chance of development of atypical hyperplasia and eventually type-1 endometrial cancer. The molecular basis of this process is still not known, since the involvement of only a minority of factors is reproducible.10 Endometrial
Risk factors and primary prevention
Women with type-1 endometrial cancer are likely to have been exposed to unopposed oestrogens (panel 2). Oestrogen-producing tumours are an uncommon risk factor. Unopposed oestrogens should no longer be used to treat postmenopausal symptoms in women who have not had hysterectomy. Excessive fat consumption and overweight (defined as body-mass index [BMI] of at least 25 kg/m2) are important risk factors present in almost 50% of women with endometrial cancer.45, 46, 47, 48, 49, 50 In premenopausal
Secondary prevention
There is no point in screening for endometrial cancer; screening is unlikely to decrease mortality from the disorder. It will mainly detect women with low-risk tumours.100 Furthermore, minimally invasive modalities potentially suitable for mass screening, including transvaginal ultrasonography (TVU) and cytology from a Pap smear or endometrial brush, have limited accuracy for the diagnosis of endometrial cancer in an asymptomatic population.101, 102 Education about the importance of
Symptoms and diagnosis
Abnormal uterine bleeding is the most frequent symptom of endometrial cancer, but many other disorders give rise to the same symptom. All postmenopausal women with vaginal bleeding and those with abnormal uterine bleeding associated with risk factors for endometrial cancer or hyperplasia (eg, polycystic ovaries, obesity, age over 40 years, erratic cycles, hormone-replacement therapy, tamoxifen use) should undergo further diagnostic endometrial assessment. The probability of endometrial cancer
Staging
Endometrial cancer is a surgically staged disease, because clinical estimates and preoperative imaging of the extent are incorrect in over 20% of cases.13 The depth of myometrial invasion and extrauterine disease (uterine serosa, adnexal involvement, peritoneal cytology, intra-abdominal, and lymph nodes) have all been incorporated into the FIGO staging scheme (table). Although the preoperative assessment of extent cannot replace FIGO staging, and it does not lead to better survival, it enables
Prognostic factors and survival
The most important prognostic features in endometrial cancer are the surgical FIGO stage, myometrial invasion, histological type, and differentiation grade; most are independent of each other (panel 3).131, 132, 133, 134, 135 Whether the 5–15% of patients with positive peritoneal cytology in the absence of extrauterine disease also classified as having stage IIIA lesions have a different outcome from those with negative cytology remains controversial.136, 137 Apart from this uncertainty, the
Surgery
The most important therapy for endometrial cancer is surgery. The procedures include acquisition of peritoneal fluid or washings for cytology, total hysterectomy including the uterine cervix, and bilateral salpingo-oophorectomy; in selected cases, there is a place for omentectomy and a thorough retroperitoneal lymph-node dissection.
Although the results of randomised trials are still lacking, in experienced hands, laparoscopy-assisted vaginal hysterectomy is feasible when operating for
Follow-up
Weight loss, pain, and vaginal bleeding can suggest recurrent disease, which mostly occurs during the first 3 years after primary treatment. Although follow-up visits are organised in most settings, retrospective data suggest that there is no difference in survival between symptomatic and asymptomatic recurrences, or between women with recurrences detected during routine follow-up visits and those with recurrences detected during the interval between routine visits.199 Furthermore, follow-up of
Search strategy and selection criteria
References (201)
Two pathogenetic types of endometrial carcinoma
Gynecol Oncol
(1983)- et al.
Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma
Gynecol Oncol
(1992) - et al.
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
Gynecol Oncol
(2003) - et al.
Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation
Hum Pathol
(1995) - et al.
Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases
Hum Pathol
(1985) - et al.
Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation
Gynecol Oncol
(2001) - et al.
Involution of PTEN-null endometrial glands with progestin therapy
Gynecol Oncol
(2004) HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?
Gynecol Oncol
(2003)- et al.
Risk factors among young women with endometrial cancer: a Danish case-control study
Am J Obstet Gynecol
(2000) - et al.
Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy
Maturitas
(1995)
Polycystic ovary syndrome and endometrial carcinoma
Lancet
Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study
Fertil Steril
Endometrial safety of hormone replacement therapy: review of literature
Maturitas
Association between uterine serous carcinoma and breast cancer
Gynecol Oncol
Longitudinal hysteroscopic follow-up during tamoxifen treatment
Lancet
Overview of the main outcomes in breast-cancer prevention trials
Lancet
Identification of women at high risk of developing endometrial cancer on tamoxifen
Eur J Cancer
Endometrial pathologies associated with postmenopausal tamoxifen treatment
Gynecol Oncol
Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial
Lancet
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients
Ann Oncol
Development of endometrial cancer after radiation treatment for cervical carcinoma
Obstet Gynecol
Familial clustering of ovarian and endometrial cancers
Eur J Cancer
Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding
Eur J Cancer
Global cancer statistics
CA Cancer J Clin
Racial differences in endometrial cancer survival: the black/white cancer survival study
Obstet Gynecol
Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival
Am J Public Health
Cancer statistics 2005
CA Cancer J Clin
Surveillance, Epidemiology, and End Results Program Public-Use Data (1973–1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission
Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953–2010
Br J Cancer
Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study
J Natl Cancer Inst
Kankerincidentie in Vlaanderen 2000
American Cancer Society guidelines for the early detection of cancer, 2003
CA Cancer J Clin
Endometrioid carcinoma of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects
Adv Anat Pathol
Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases
Am J Surg Pathol
Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma
Semin Diagn Pathol
FIGO stage 1988 revision
Gynecol Oncol
The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system
Cancer
A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advanced-stage tumors with favourable prognosis
Am J Surg Pathol
Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type
Histopathology
Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma
Am J Surg Pathol
Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation
Am J Surg Pathol
Clear cell carcinoma of the endometrium: a histopathological and clinical study of 31 cases
Cancer
Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases
Am J Surg Pathol
Stage IA uterine serous carcinoma: a study of 13 cases
Am J Surg Pathol
Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis
Am J Surg Pathol
Simultaneous presentation of carcinoma involving the ovary and the uterine corpus
Cancer
A molecular genetic and statistical approach for the diagnosis of dual-site cancers
J Natl Cancer Inst
Endometrial carcinoma
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancer
J Natl Cancer Inst
Changes in endometrial PTEN expression throughout the human menstrual cycle
J Clin Endocrinol Metab
Cited by (1400)
ECMS-NET:A multi-task model for early endometrial cancer MRI sequences classification and segmentation of key tumor structures
2024, Biomedical Signal Processing and ControlDevelopment of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma
2024, Scientific Reports